SpineGuard Strengthens Its US Organization
15 April 2021 - 6:00PM
Business Wire
Regulatory News:
SpineGuard (FR0011464452 – ALSGD), an innovative company
that deploys its DSG® (Dynamic Surgical Guidance) sensing
technology to secure and streamline the placement of bone implants
announced today the appointment of Patrick Pilcher as Vice
President of Sales & Marketing for the United States, effective
May 3, 2021.
Patrick Pilcher joins SpineGuard as Vice President of Sales and
Marketing with the U.S. responsibility for driving distribution
channel development, launching the new DSG Connect platform and
contributing to industry partnership activities to further leverage
DSG, SpineGuard’s core technology.
Mr. Pilcher has over 30 years of sales, sales management,
marketing and business development experience in the medical device
and peripheral spine surgery arena. Over the course of his career,
his areas of expertise were tied to spinal fusion, dynamic
stabilization, motion preservation, neuromonitoring, and
orthobiologic modalities. During that time, he held roles in both
legacy corporations such as Medtronic (SDG), Zimmer and start-ups
with Spinal Concepts (Abbott), Pioneer Surgical (Surgalign),
Surgical Monitoring (Sentient Medical), Spinal Elements, AlloSource
and CellRight Technologies.
Pierre Jérôme, co-founder, Chairman and CEO of SpineGuard,
said: “With U.S. profitable operations, the FDA clearance of
our DSG Connect platform and a secured cash runway, the right
conditions are now in place for strengthening our US organization.
I am thrilled to welcome Patrick aboard! His passion for meaningful
medtech innovation and extensive US spine industry experience in
shaping and driving the execution of growth strategies make him the
suitable leader we need to move our U.S. business forward and
expand the adoption of our DSG technology.”
Patrick Pilcher added: “I am excited at the opportunity
to join this seasoned team and drive SpineGuard in the U.S. to
further integrate its elegant, and technologically advanced DSG
solutions into the mainstream of the evolving paradigm of spinal
instrumentation. Our mantra remains in promoting the safest means
of bony fixation with a significant reduction of radiation and
time, while mitigating the inherent risks of neuro-vascular
insults. We are poised to bring safety and confidence to any
hospital or surgery center where spine cases using pedicle fixation
are performed addressing a range of cases from primary to complex
deformities.”
2021 Perspectives
SpineGuard is focusing on the following priorities while
investing selectively to remain close to breakeven:
- Boost commercial activities with the launch of the DSG-Connect
visual interface.
- Accelerate the implementation of the DSG digital technology in
the surgical robotic field through the deployment of AI algorithms,
new scientific evidence, and additional patents.
- Intensify the collaboration with ConfiDent ABC for the dental
application and co-develop a new generation of products embedding
the DSG technology.
- Affirm the company’s technological shift and sign new strategic
partnerships in particular for the use of DSG technology in the
robotic field.
Next financial press release: 2021 half-year revenue on
July 7, 2021
About SpineGuard®
Founded in 2009 in France and the USA by Pierre Jérôme and
Stéphane Bette, SpineGuard is an innovative company deploying its
proprietary radiation-free real time sensing technology DSG®
(Dynamic Surgical Guidance) to secure and streamline the placement
of implants in the skeleton. SpineGuard designs, develops and
markets medical devices that have been used in over 80,000 surgical
procedures worldwide. Sixteen studies published in peer-reviewed
scientific journals have demonstrated the multiple benefits DSG®
offers to patients, surgeons, surgical staff and hospitals.
Building on these solid fundamentals and several strategic
partnerships, SpineGuard has expanded its technology platform in a
disruptive innovation: the « smart » pedicle screw launched late
2017 and is broadening the scope of applications in dental
implantology and surgical robotics. DSG® was co-invented by Maurice
Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem,
Biomedical Engineer.
For further information, visit www.spineguard.com
Disclaimer
The SpineGuard securities may not be offered or sold in the
United States as they have not been and will not be registered
under the Securities Act or any United States state securities
laws, and SpineGuard does not intend to make a public offer of its
securities in the United States. This is an announcement and not a
prospectus, and the information contained herein does and shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of the securities referred to herein in
the United States in which such offer, solicitation or sale would
be unlawful prior to registration or exemption from
registration.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210415005540/en/
SpineGuard Pierre Jérôme Chairman and CEO Tél. : +33 1 45
18 45 19 p.jerome@spineguard.com Manuel Lanfossi Chief Financial
Officer m.lanfossi@spineguard.com Europe / NewCap Investor
Relations & Financial Communication Mathilde Bohin / Pierre
Laurent Tél. : +33 1 44 71 94 94 spineguard@newcap.eu
Spineguard (EU:ALSGD)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Spineguard (EU:ALSGD)
Historical Stock Chart
Von Apr 2023 bis Apr 2024